Investor Overview

Investor Overview

Corporate Profile

Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. Y-mAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.

Stock Quote

Minimum 15 minutes delayed. Source: LSEG

News Releases

May 07, 2025

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 06, 2025

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

Apr 27, 2025

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting